Efficacy prediction of cevimeline in patients with Sjögren’s syndrome
- 13 January 2007
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 26 (8), 1320-1327
- https://doi.org/10.1007/s10067-006-0507-8
Abstract
The objective of this study was to examine the clinical and immunological factors influencing the efficacy of cevimeline hydrochloride hydrate (cevimeline) for the treatment of xerostomia in patients with Sjögren’s syndrome (SS). Thirty primary SS patients who were medicated with cevimeline were enrolled in this study. Whole stimulated sialometry (WSS) was compared between pre- and posttreatment points (4 weeks after oral cevimeline administration) and the increment rate of WSS was calculated. Multiple regression was employed to examine the relative contributions of the clinical and immunological factors, including age, pretreatment WSS, duration of disease, sialography, minor salivary gland biopsy, anti-Ro/SS-A antibodies, anti-La/SS-B antibodies, and antibodies to muscarinic type 3 receptors to the posttreatment WSS. Patients with normal sialography findings, negative minor salivary gland biopsy, and absence of anti-La/SS-B antibodies had significantly higher increment rates of WSS compared with those with positive findings (p = 0.042, 0.002, and 0.018, respectively). Results of the multiple regression analysis showed that sialography (coefficient = −0.867, p = 0.004) and minor salivary gland biopsy (coefficient = −0.869, p = 0.003) had significant associations with the posttreatment WSS. Our preliminary results demonstrated the relationship between the effect of cevimeline on saliva secretion and the degree of salivary gland destruction evaluated by sialography and histopathological findings in the labial minor salivary glands. These diagnostic approaches could provide useful prognostic information on the efficacy of cevimeline in SS patients.Keywords
This publication has 23 references indexed in Scilit:
- Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cellsArthritis & Rheumatism, 2006
- Detection of anti–type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assayArthritis & Rheumatism, 2004
- Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral PilocarpineJCR: Journal of Clinical Rheumatology, 2004
- Muscarinic acetylcholine receptor autoantibodies in patients with Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2004
- Salivary Enhancement TherapiesCaries Research, 2004
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- A double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis siccaArthritis & Rheumatism, 2002
- Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD miceArthritis & Rheumatism, 2000
- Alterations in the Secretory Response of Non-obese Diabetic (NOD) Mice to Muscarinic Receptor StimulationClinical Immunology and Immunopathology, 1996
- Saliva: its secretion, composition and functionsBritish Dental Journal, 1992